Back to today’s briefing

Story perspectives

Trametinib Reduces Mortality in Children with HCM

1/9/2025

36 7

Summary

Story summary

A groundbreaking study in JACC: Basic to Translational Science reveals that trametinib, a MEK inhibitor, dramatically lowers mortality and morbidity in children suffering from severe hypertrophic cardiomyopathy (HCM) related to RASopathies. Involving 61 young participants, the trial highlights trametinib's promise where traditional treatments fall short, paving the way for further exploration of its long-term benefits and ideal dosage.

1 of 1

Story summary

A groundbreaking study in JACC: Basic to Translational Science reveals that trametinib, a MEK inhibitor, dramatically lowers mortality and morbidity in children suffering from severe hypertrophic cardiomyopathy (HCM) related to RASopathies. Involving 61 young participants, the trial highlights trametinib's promise where traditional treatments fall short, paving the way for further exploration of its long-term benefits and ideal dosage.